



COVID-19 VACCINE

PROVIDER INFORMATION

MEDICAL ASSOCIATION OF THE STATE OF ALABAMA



TABLE OF CONTENTS

Comparing the Pfizer and Moderna Vaccines	Page 03
Pfizer Prioritization of Office-Based Physicians	Page 04
Pfizer Vaccine Allocation	Page 05
Shipping and Storage of the Pfizer Vaccine	Page 06
Enroll to be a Vaccine Provider	Page 07
Billing/Coding the Vaccine	Page 10
COVID-19 Vaccine Frequently Asked Questions	Page 15
COVID-19 Talking Points	Page 17
Draft Social Media Posts	Page 18
Other Resources	Page 20



PFIZER VS. MODERNA

PFIZER

First round of vaccines will be administered at 15 designated hospitals

Must be stored at -80 Celsius

975 dose minimum order

Must be reconstituted

Considered fragile

Reports >90% effective rate

Needs 2 doses (21 days apart)

MODERNA

Best suited for office-based physicians

Must be stored at -20 Celsius

100 dose minimum order

No onsite mixing needed

Cannot mix the vaccine types

Reports >90% effective rate

Needs 2 doses (28 days apart)





PFIZER VACCINE PRIORITIZATION FOR OFFICE-BASED PHYSICIANS

Beginning this week, 40,000 doses of the Pfizer vaccine are being shipped to 15 locations in Alabama (see the list on page 4). Healthcare workers, including all physicians, are in the first group of people with the opportunity to get vaccinated.

However, because the initial supply of the vaccine will be limited, it is necessary for the Alabama Department of Public Health (ADPH) to prioritize who will receive the initial doses. Prioritization plans were developed by the ADPH and external partners.

The following is a list of physician categories that have been prioritized for the initial doses. As more vaccines are shipped to Alabama in the coming weeks, additional categories of physicians will be prioritized. This will continue until all physicians have the ability to receive the vaccine.


- Any physician 65 years of age or older with underlying chronic health conditions who has not tested positive for COVID in the last 90 days and who is in direct physical contact with patients.
- Any health care worker, nurse, PA, or aide 65 years or older with underlying chronic health conditions who have not tested positive for COVID in the last 90 days, who works with a physician and is in direct physical contact with patients.
- Physicians, nurses, PA's and aides working in an Urgent Clinic or a primary care office who have not tested positive for COVID in the last 90 days and is in direct physical contact with patients. This does NOT include a practice doing only well visits.

**Physicians who are hospital-based or who are seeing COVID patients primarily in a hospital setting will be covered with the dose allocation from the hospital. This would include ER physicians, pulmonology, anesthesiologists, radiology, infectious disease etc.*

*** Medical Directors of Nursing Homes are not on this list. They will get vaccinated directly through the nursing home onsite at the facility. The "Nursing Home Program" will receive their allotment in the 2nd round of vaccine shipments towards the end of December. Medical Directors should contact their facility for more details.*

Additional information about the stratification for physicians and their office staff will be forthcoming as additional vaccines become available in the coming days and weeks.





PFIZER VACCINE ALLOCATION

For appointment dates and times, [click here](#).

Athens Limestone Hospital

Baptist Medical Center South

Cullman Regional Medical Center

DCH Regional Medical Center

East Alabama Medical Center

Huntsville Hospital

Infirmery Employee Health - Thomas Hospital

Infirmery Employee Health - Mobile Infirmery

Lake Martin Community Hospital

Providence Hospital

Southeast Health

Springhill Memorial Hospital

UAB Employee Health

USA Children's & Women's Hospital

USA Health University Hospital



SHIPPING AND STORAGE OF THE PFIZER VACCINE

Direct Shipments to Vaccination Center by Transport Courier



- Pfizer has designed a distribution model which is built on a flexible just in time system to ship the vaccine from manufacturing site and/or storage facility directly to the points of vaccination.

Temperature & Location Tracking During Transportation



- Each thermal shipper has reusable **GPS enabled temperature monitoring device** which will be enabled when the shipper is packed.
- All shipments will be tracked via the onboard GPS monitoring device to **ensure end-to-end distribution within required temperatures.**

Storage and dosing at point of vaccination

Refrigerator 2 to 8°C up to 5 days

Vials in Refrigerator (Undiluted)

- Can be stored at 2 to 8°C up to 5 days




Time to Thaw Vials Prior to Dilution

Refrigerator (2 to 8°C)	Up to 3 hours (1 vial tray)
Room Temperature	30 minutes

†Do not refreeze thawed vials

Post Dilution

- Use within 6 hours from the time of dilution



ENROLL TO BE A MODERNA VACCINE PROVIDER

If you enroll in ImmPRINT, please be advised that you are enrolling to become a provider of the COVID-19 vaccine for your patients, once it is made available to the general public.

Each vaccination site within an organization must enroll in ImmPRINT to participate in the COVID-19 vaccine program. If your site is already enrolled in ImmPRINT, you do not need to re-enroll. Go to "Complete the COVID-19 Provider Agreement and Profile".

ENROLL IN ImmPRINT

To enroll in ImmPRINT, please go online:

<https://siis.state.al.us/ImmPRINT/login/login.aspx>

1. Complete Initial Site Enrollment Agreement
2. Immunization staff will review, verify, and approve your agreement.
3. Your site will be contacted by Immunization Division (IMM) Field Compliance Staff to conduct ImmPRINT training for the site administrator, either via WebEx, FaceTime or by phone and pictures.
4. Site Administrator activates site users.



COMPLETE COVID-19 PROVIDER AGREEMENT AND PROFILE

To complete the COVID-19 Provider Agreement and Profile:

1. Log in to ImmPRINT,
<https://siis.state.al.us/ImmPrint/login/login.aspx>, after the ImmPRINT enrollment process is complete.
2. Click on ImmPRINT Registry widget
3. Click Special Projects
4. Select COVID-19 Enrollment Form
5. Complete the Provider Agreement and Profile, which includes:
 - a) Provider address and contact information
 - b) Chief Medical Officer and Chief Executive Officer contact information
 - c) Primary COVID-19 Vaccine Coordinator & Vaccine Back-Up Coordinator
 - Both are required to complete vaccine storage & handling training consisting of “You Call the Shots”-Module Ten-Storage and Handling-2020 weblink
<https://www2a.cdc.gov/nip/isd/ycts/mod1/courses/sh/ce.asp>
 - Continuing education and download certificate instruction weblink <https://tceols.cdc.gov/Home/Steps>
 - Upload of certificate of completion into this profile agreement required BEFORE contacted by Immunization field compliance staff to complete training
 - d) Contact Information for the Sites Back-Up COVID-19 Vaccine Coordinator
 - e) Site Shipment Address
 - f) Days and Times to deliver the vaccine
 - g) Select Provider Type



COMPLETE COVID-19 PROVIDER AGREEMENT AND PROFILE (CONTINUED)

h) Choose the vaccinating location setting

i) Estimate the number of staff and patient your site may serve

6. Immunization staff will review responses, verify licenses, OIG list, and authorize your COVID-19 agreement.

7. Your site will be contacted by Immunization Division (IMM) Field Compliance Staff to conduct ImmPRINT, agreement, profile, and vaccine storage and handling training for the site administrator, either via WebEx, FaceTime, or by phone with pictures of storage units and thermometers.

8. Once activated, your site will be notified to order the COVID-19 vaccine in ImmPRINT through the Vaccine Ordering Management System.

Please note: Due to the phased approach for vaccine distribution, providers may be prioritized for COVID-19 vaccine ordering based on the volume of the critical population served. ImmPRINT will send you an email when your vaccination location may order the COVID-19 vaccine.

Phased Approach to COVID-19 Vaccination:

- Phase 1: Potentially limited doses available
- Phase 2: Large number of doses available
- Phase 3: Sufficient supply of doses available

ENROLLMENT

APPROVAL

TRAINING

ORDERING



BILLING/CODING THE COVID-19 VACCINE

We are working with Blue Cross Blue Shield of Alabama, Alabama Medicaid, and other insurance carriers to gather more information on the specifics of billing and coding the COVID-19 vaccine. This toolkit will be updated as more details become available.

CMS COVID-19 Vaccine Part B Billing Policy

- Current Medicare Providers: If you're enrolled in Medicare under institutional or non-institutional provider types, you don't need to take any action to administer and bill the COVID-19 shot.
- New Medicare Providers: can enroll as "Medicare mass immunizers" through an expedited 24-hour process. The ability to easily enroll as a mass immunizer is important for some pharmacies, schools, senior centers, and entities that may be non-traditional providers or otherwise not eligible for Medicare enrollment.
- Mass Immunization Clinics: Section 4 of the Form CMS-855, the supplier need NOT list each off-site location (e.g., county fair, shopping mall). It need only list its base of operation:
 - NIP and TIN of location of standing orders physician is used as the rendering provider
 - Place of service 60 is indicated in an offsite immunization setting




CMS Payment Allowances for COVID-19 Vaccines and their Administration during the Public Health Emergency

Code	CPT Short Descriptor	Labler Name	Vaccine/Procedure Name	Payment Allowance
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	Pfizer-Biontech Covid-19 Vaccine	\$0.01
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration - First Dose	\$16.94
0002A	ADM SARSCOV2 30MCG/0.3ML 2ND	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration - Second Dose	\$28.39
91301	SARSCOV2 VAC 100MCG/0.5ML IM	Moderna	Moderna Covid-19 Vaccine	\$0.01
0011A	ADM SARSCOV2 100MCG/0.5ML1ST	Moderna	Moderna Covid-19 Vaccine Administration - First Dose	\$16.94
0012A	ADM SARSCOV2 100MCG/0.5ML2ND	Moderna	Moderna Covid-19 Vaccine Administration - Second Dose	\$28.39

[More information from CMS
on coding the COVID-19 Vaccine](#)








PFIZER VACCINE

2 DOSES AT 0 & 21 DAYS

-112 TO -76°F

Box Label

NDC 59267-1000-2		NO COPY	
Pfizer-BioNTech COVID-19 Vaccine Suspension for Intramuscular Injection 195 Multiple Dose Vials (after dilution each vial contains 5 doses of 0.3 mL)		 Manufactured by Pfizer Inc. New York, NY 10017 Manufactured for BioNTech Manufacturing GmbH An der Goldgrube 12 55131 Mainz, Germany	
 STORAGE: Prior to dilution, store at -80°C to -60°C (-112°F to -76°F). Store in this carton to protect from light. DOSAGE AND ADMINISTRATION: After dilution, each vial contains 5 doses of 0.3 mL. See FDA-authorized Fact Sheet or scan QR code for information. MUST BE DILUTED BEFORE USE with sterile 0.9% Sodium Chloride Injection, USP (not supplied). After dilution, store the vaccine at 2°C to 25°C (35°F to 77°F). Discard after 6 hours. Contains no preservative. For use under Emergency Use Authorization.		 359267100023 FP0 UPC © 100%	
Rx only		PAA156052	
NO COPY		LOT: IMPRINT AREA (reads this way) EXP: NO VARNISH NO COPY, NO INK,	
NO COPY		PAA156052	
Pfizer-BioNTech COVID-19 Vaccine Suspension for Intramuscular Injection 195 Multiple Dose Vials (after dilution each vial contains 5 doses of 0.3 mL) STORAGE: Prior to dilution, store at -80°C to -60°C (-112°F to -76°F). Store in this carton to protect from light. DOSAGE AND ADMINISTRATION: After dilution, each vial contains 5 doses of 0.3 mL. See FDA-authorized Fact Sheet or scan QR code for information.		MUST BE DILUTED BEFORE USE with sterile 0.9% Sodium Chloride Injection, USP (not supplied). After dilution, store the vaccine at 2°C to 25°C (35°F to 77°F). Discard after 6 hours. Contains no preservative.	
NO COPY		LOT: IMPRINT AREA (reads this way) EXP: NO VARNISH NO COPY, NO INK,	

59267-1000-01 vial NDC

59267-1000-02 carton NDC


59267-1000-03 diluent NDC

91300 vaccine CPT \$.00 or \$.01


0001A dose 1 CPT \$16.94

0002A dose 2 CPT \$28.39

Vial Label

LOT/EXP PAA156051	Pfizer-BioNTech COVID-19 Vaccine After dilution, vial contains 5 doses of 0.3 mL. For intramuscular use. Contains no preservative. For use under Emergency Use Authorization. DILUTE BEFORE USE. Discard 6 hours after dilution when stored at 2 to 25°C (35 to 77°F). Dilution date and time:	 NDC 59267-1000-1 FP0 USG Dose/Exp





MODERNA VACCINE

2 DOSES AT 0 & 28 DAYS

-13 TO 5°F

Box Label



80777-273-99 carton NDC

80777-273-10 vial NDC

91301 vaccine CPT \$.00 or \$.01

0011A dose 1 CPT \$16.94

0012A dose 2 CPT \$28.39

Vial Label



UNINSURED PATIENTS AND THE VACCINE ADMIN FEE:

HRSA recently partnered with UHC's Optum Pay for uninsured covid testing and treatment claims. The vaccine administration fee was recently added.

All providers must register with Optum to submit uninsured claims for the administration fee only.

Groups that are signed up with Medicare that DO NOT have to reenroll as Mass Immunizers include: hospitals, physicians, clinic/group practices, hospital outpatient departments, skilled nursing facilities, critical access hospitals, end-stage renal disease facilities, home health agencies, hospice, comprehensive outpatient rehabilitation facilities, federally qualified health centers, rural health clinics, and Indian health services facilities.

Temporary patient IDs need to be generated prior to claim submission and all claims should be final with no corrections.

You will need a DL# or SS# for all uninsured patient claims.

CLAIM REQUIREMENTS



COVID-19 VACCINE FAQs

Which COVID-19 vaccines are expected to be available first?

Pfizer - 2 doses 21 days apart - Approved for EUA

Moderna - 2 doses 28 days apart - Requested EUA

Johnson & Johnson - 1 dose - phase 3 clinical trial

Oxford/AstraZeneca - 2 doses 28 days apart - phase 3 clinical trial

What is an Emergency Use Authorization (EUA)?

Emergency Use Authorization occurs when the FDA allows a drug or vaccine to be used during a public health emergency. The FDA may choose to grant EUA once studies have demonstrated the safety and effectiveness of a vaccine. EUAs provide timely access to critical medical products during a medical emergency when there are no sufficient treatments or vaccines available.

Which pharmaceutical company will provide the vaccine?

Pfizer was the first manufacturer to be approved for emergency use authorization. Moderna has also requested emergency use authorization.

Will the COVID-19 vaccines be safe?

To date, no serious safety concerns have been reported by an independent Data and Safety Monitoring Board overseeing Phase 3 trials of the Pfizer and Moderna mRNA COVID-19 vaccines. After receiving the Pfizer vaccine, only fatigue (3.8%) and headache (2%) occurred at a rate greater than or equal to 2%.

COVID-19 VACCINE FAQS(CONTINUED)

If you develop COVID-19 symptoms after getting the vaccine should you quarantine?

Yes, it typically takes a few weeks for the body to build immunity after vaccination. That means it is possible a person could be infected with the virus that causes COVID-19 just before or just after vaccination and get sick. This is because the vaccine has not had enough time to provide protection.

How effective will the vaccines be?

In Phase 3 trials, the Pfizer vaccine showed a 95% efficacy rate 7 days after the second dose. The vaccine was 94% effective in adults >65 years old. The Moderna vaccine showed a 94% efficacy rate 14 days after the second dose. These results were consistent across gender, age, race, and ethnicity.

How long will immunity last after I get vaccinated? Will I need to be vaccinated every year?

The length of immunity following vaccination is not yet known for COVID-19. Given the novel nature of this virus and vaccine development, long term data is not yet available to guide future vaccine protocols.

Can I take the vaccine if I have already had COVID and recovered? How long after can I take it?

It is currently unknown how long natural immunity lasts after recovering from COVID-19. Early studies show that it is not long-lasting, and cases of reinfection have been reported. The Pfizer trial did include individuals who previously had COVID and recovered but data from that group is still pending. The Advisory Committee on Immunization Practices (ACIP) will be making recommendations on which individuals should be vaccinated.



COVID-19 VACCINE TALKING POINTS FOR YOUR PATIENTS

- COVID-19 vaccination will help to protect us from the virus and save lives.
- Based on months of clinical trials, COVID-19 vaccines that receive FDA Emergency Use Authorization have met rigorous and scientific standards of safety, quality, and effectiveness.
- Clinical trials with tens of thousands of people have demonstrated that vaccination is highly effective in preventing COVID-19 and caused no serious safety concerns. (The only adverse reactions documented after being vaccinated included mild fatigue and a headache, which only occurred shortly after being vaccinated and then went away.)
- COVID-19 vaccines will not give you COVID-19. (None of the COVID-19 vaccines currently in development in the U.S. use the live virus that causes COVID-19. COVID-19 vaccines cause an immune response in your body, but do not give you the virus.)
- Getting vaccinated will help to protect the health and wellbeing of our communities and get the economy moving again.
- COVID-19 vaccination will offer a path forward to ensure our state's essential workers can safely do their jobs and provide for their families.
- Getting vaccinated not only protects you, but the people around you – particularly those at risk of severe COVID-19 illness.
- When communities are vaccinated, fewer people are likely to get sick, saving taxpayers dollars and assuring the healthcare system can continue to meet the needs of those it is intended to serve.
- It is vital that each of us continues to do their part to prevent the spread of the virus.
- Stopping a pandemic requires using all the tools we have available, and vaccination is just one of those tools.
- Continue to wear a mask, stay physically distanced, wash your hands frequently, and avoid the three Cs – crowds, closed indoor spaces, and close contacts.



DRAFT SOCIAL MEDIA POSTS ABOUT #COVID19VACCINE

Recommended Use: Adapt these social media posts to use on social media platforms.

- Vaccines have two benefits: 1) protecting those who are vaccinated and 2) when vaccination rates are high, they create herd immunity, disrupting the spread of disease and protecting those who cannot be vaccinated. Here's how herd immunity works in a community with high vaccination rates: (herd immunity GIF can be downloaded from <https://imgur.com/gallery/8M7q8#J7LANQ4> then posted in social media platforms)
- As we await a #COVID19Vaccine locally, we have been working with the Alabama Department of Public Health (ADPH) to plan for when #COVID19Vaccine is available.
- #COVID19Vaccines are currently being developed and tested for their safety and efficacy (effectiveness in clinical trials). The Pfizer and Moderna vaccines recently completed this process and have requested an Emergency Use Authorization (EUA) from the @US_FDA so that their vaccines can soon be used in the U.S. in response to the #COVID-19 pandemic. The FDA describes what an EUA is in this short video: <https://www.youtube.com/watch?v=iGkwaESsGBQ>
- During a public health emergency, emergency use authorizations (EUAs) can be used by the @US_FDA to help make medical products available quickly. For a vaccine to receive an EUA, the FDA must determine if the vaccine's benefits outweigh its risks based on data from Phase 3 clinical trial(s), which demonstrates the vaccine's safety and efficacy (effectiveness in clinical trials). The @US_FDA describes what an EUA is in this short video: <https://www.youtube.com/watch?v=iGkwaESsGBQ>



DRAFT SOCIAL MEDIA POSTS (CONTINUED)

- Once a #COVID19Vaccine is authorized for use, the Advisory Committee on Immunization Practices will make recommendations to the @CDCGOV director on how the vaccine should be used. But who is the ACIP? They are an external team of medical and infectious disease experts who are responsible for making recommendations on how to use vaccines to control diseases in the U.S. Learn more here: <https://www.CDC.gov/vaccines/acip/committee/role-vaccine-recommendations.html>
- Ensuring the safety of vaccines, including the #COVID19Vaccines, is a top priority. The U.S. vaccine safety system is designed to ensure that all vaccines are as safe as possible. Learn more about the steps that are being taken to ensure the safety of #COVID19Vaccines: www.CDC.gov/coronavirus/2019-ncov/vaccines/safety.html.
- The federal government has committed to providing free or low-cost #COVID19Vaccines. However, there may be a fee for administering the vaccine that most public and private insurance companies will cover, so there is no cost for the person getting vaccinated. In addition, those without health insurance will be able to get the #COVID19Vaccines at no cost.
- The two leading #COVID19Vaccine candidates are mRNA vaccines. This brief video from STAT news explains how #COVID19Vaccines based on messenger RNA technology work: <https://www.youtube.com/watch?v=S8Wd-NMqvno>.


TWITTER

The @US_FDA may grant an Emergency Use Authorization (EUA) for a vaccine that shows that its benefits outweigh its risks so that it may be used to quickly respond to the pandemic. The FDA describes what an EUA is in this short video:

<https://www.youtube.com/watch?v=iGkwaESsGBQ>

A committee of external medical and public health experts advises CDC on U.S. vaccine recommendations. If a #COVID19 vaccine is authorized or approved, this committee will vote on whether to recommend it and who should receive it. Learn more: <https://www.CDC.gov/vaccines/acip/committee/role-vaccine-recommendations.html>





OTHER COVID-19 VACCINE RESOURCES

- [FDA FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE](#)
- [EMERGENCY USE AUTHORIZATION FOR VACCINES EXPLAINED](#)
- [FDA NEWS RELEASE: FDA TAKES KEY ACTION IN FIGHT AGAINST COVID-19 BY ISSUING EMERGENCY USE AUTHORIZATION FOR FIRST COVID-19 VACCINE](#)
- [CMS TOOL KIT \(UPDATED DAILY\)](#)

